Repeated nicotine administration robustly increases bPiDDB inhibitory potency at α6β2-containing nicotinic receptors mediating nicotine-evoked dopamine release

Biochemical Pharmacology

Volumn 80, Issue 3, 2010, Pages 402-409

  Smith, Andrew M ^a   Pivavarchyk, Marharyta ^a   Wooters, Thomas E ^b   Zhang, Zhenfa ^a   Zheng, Guangrong ^a   McIntosh, J Michael ^c   Crooks, Peter A ^a   Bardo, Michael T ^b   Dwoskin, Linda P ^a,b  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine release; Nicotine; Nicotinic acetylcholine receptor; Nicotinic receptor antagonist; Smoking cessation

Indexed keywords

ALPHA CONOTOXIN MII; DOPAMINE; N,N' DODECANE 1,12 DIYL BIS 3 PICOLINIUM DIBROMIDE; N,N' DODECANE 1,12 DIYL BIS 3 PICOLINIUM DIBROMIDE DERIVATIVE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA6BETA2; NICOTINIC RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; EVOKED RESPONSE; IC 50; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RAT; RECEPTOR BLOCKING; STOICHIOMETRY; STRIATE CORTEX;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DRUG SYNERGISM; MALE; NICOTINE; NICOTINIC ANTAGONISTS; PICOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

EID: 77953363468     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.03.018     Document Type: Article

References (52)

1. George T.P., O'Malley S.S. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004, 25:42-48.
2. Le Foll B., Goldberg S.R. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handbook Exp Pharmacol 2009, 192:335-367.
3. Balfour D.J. The neurobiology of tobacco dependence: a commentary. Respiration 2002, 69:7-11.
4. Mathieu-Kia A.M., Kellogg S.H., Butelman E.R., Kreek M.J. Nicotine addiction: insights from recent animal studies. Psychopharmacology 2002, 162:102-118.
5. Goldberg S.R., Spealman R.D., Goldberg D.M. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science (New York, NY) 1981, 214:573-575.
6. Corrigall W.A., Coen K.M. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 1989, 99:473-478.
7. Markou A., Paterson N.E. The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res 2001, 3:361-373.
8. Harvey D.M., Yasar S., Heishman S.J., Panlilio L.V., Henningfield J.E., Goldberg S.R. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology 2004, 175:134-142.
9. Shoaib M., Schindler C.W., Goldberg S.R. Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology 1997, 129:35-43.
10. Rauhut A.S., Mullins S.N., Dwoskin L.P., Bardo M.T. Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther 2002, 303:664-672.
11. Corrigall W.A., Franklin K.B., Coen K.M., Clarke P.B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992, 107:285-289.
12. Rahman S., Zhang Z., Papke R.L., Crooks P.A., Dwoskin L.P., Bardo M.T. Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo. Br J Pharmacol 2008, 153:792-804.
13. Salminen O., Murphy K.L., McIntosh J.M., Drago J., Marks M.J., Collins A.C., et al. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 2004, 65:1526-1535.
14. Salminen O., Drapeau J.A., McIntosh J.M., Collins A.C., Marks M.J., Grady S.R. Pharmacology of α-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. Mol Pharmacol 2007, 71:1563-1571.
15. Grady S.R., Salminen O., Laverty D.C., Whiteaker P., McIntosh J.M., Collins A.C., et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 2007, 74:1235-1246.
16. Lopez-Hernandez G.Y., Sanchez-Padilla J., Ortiz-Acevedo A., Lizardi-Ortiz J., Salas-Vincenty J., Rojas L.V., et al. Nicotine-induced up-regulation and desensitization of α4β2 neuronal nicotinic receptors depend on subunit ratio. J Biol Chem 2004, 279:38007-38015.
17. Sallette J., Pons S., Devillers-Thiery A., Soudant M., Prado de Carvalho L., Changeux J.P., et al. Nicotine upregulates its own receptors through enhanced intracellular maturation. Neuron 2005, 46:595-607.
18. Corringer P.J., Sallette J., Changeux J.P. Nicotine enhances intracellular nicotinic receptor maturation: a novel mechanism of neural plasticity?. J Physiol Paris 2006, 99:162-171.
19. Harkness P.C., Millar N.S. Changes in conformation and subcellular distribution of α4β2 nicotinic acetylcholine receptors revealed by chronic nicotine treatment and expression of subunit chimeras. J Neurosci 2002, 22:10172-10181.
20. Marks M.J., Burch J.B., Collins A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther 1983, 226:817-825.
21. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 1992, 41:31-37.
22. Nashmi R., Xiao C., Deshpande P., McKinney S., Grady S.R., Whiteaker P., et al. Chronic nicotine cell specifically upregulates functional α4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. J Neurosci 2007, 27:8202-8218.
23. McCallum S.E., Collins A.C., Paylor R., Marks M.J. Deletion of the β2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation. Psychopharmacology 2006, 184:314-327.
24. Perry D.C., Mao D., Gold A.B., McIntosh J.M., Pezzullo J.C., Kellar K.J. Chronic nicotine differentially regulates α6- and β3-containing nicotinic cholinergic receptors in rat brain. J Pharmacol Exp Ther 2007, 322:306-315.
25. Perez X.A., Bordia T., McIntosh J.M., Grady S.R., Quik M. Long-term nicotine treatment differentially regulates striatal α6α4β2* and α6(non-α4)β2* nAChR expression and function. Mol Pharmacol 2008, 74:844-853.
26. Perez X.A., O'Leary K.T., Parameswaran N., McIntosh J.M., Quik M. Prominent role of alpha3/alpha6beta2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatment. Mol Pharmacol 2009, 75:938-946.
27. Mao D., Perry D.C., Yasuda R.P., Wolfe B.B., Kellar K.J. The α4β2α5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. J Neurochem 2008, 104:446-456.
28. Dwoskin L.P., Sumithran S.P., Zhu J., Deaciuc A.G., Ayers J.T., Crooks P.A. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg Med Chem Lett 2004, 14:1863-1867.
29. Dwoskin L.P., Wooters T.E., Sumithran S.P., Siripurapu K.B., Joyce B.M., Lockman P.R., et al. N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-induced dopamine release and hyperactivity. J Pharmacol Exp Ther 2008, 326:563-576.
30. Rahman S., Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P., Bardo M.T. The effects of a novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology 2007, 52:755-763.
31. Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P., Bardo M.T. Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology 2006, 184:426-434.
32. Dwoskin L.P., Smith A.M., Wooters T.E., Zhang Z., Crooks P.A., Bardo M.T. Nicotinic receptor antagonist-based therapies and candidates for smoking cessation. Biochem Pharmacol 2009, 78:732-743.
33. Cartier G.E., Yoshikami D., Gray W.R., Luo S., Olivera B.M., McIntosh J.M. A new α-conotoxin which targets α3β2 nicotinic acetylcholine receptors. J Biol Chem 1996, 271:7522-7528.
34. Ayers J.T., Dwoskin L.P., Grinevich V.P., Deaciuc A.G., Crooks P.A. bis-Azaaromatic quaternary ammonium analogs: ligands for α4β2* and α7* subtypes of neuronal nicotinic receptors. Bioorg Med Chem Lett 2002, 12:3067-3071.
35. Zhang Z, Zheng G, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Novel bis-, tris-, and tetrakis-tertiary amine antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release; unpublished results.
36. 3H] dopamine overflow from superfused rat striatal slices. J Pharmacol Exp Ther 2003, 306:1011-1020.
37. 3H-dopamine. J Pharmacol Exp Ther 1997, 283:778-787.
38. Papke R.L., Dwoskin L.P., Crooks P.A., Zheng G., Zhang Z., McIntosh J.M., et al. Extending the analysis of nicotinic receptor antagonists with the study of α6 nicotinic receptor subunit chimeras. Neuropharmacology 2008, 54:1189-1200.
39. Lockman P.R., Manda V.K., Geldenhuys W.J., Mittapalli R.K., Thomas F., Albayati Z.F., et al. Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide at the blood-brain barrier. J Pharmacol Exp Ther 2008, 324:244-250.
40. Albayati Z.A., Dwoskin L.P., Crooks P.A. Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. Drug Metab Dispos 2008, 36:2024-2029.
41. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000, 44:235-249.
42. Pharma Algorithms, http://www.pharma-algorithms.com/webboxes/.
43. Janson A.M., Meana J.J., Goiny M., Herrera-Marschitz M. Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: a microdialysis study. Neurosci Lett 1991, 134:88-92.
44. Grilli M., Parodi M., Raiteri M., Marchi M. Chronic nicotine differentially affects the function of nicotinic receptor subtypes regulating neurotransmitter release. J Neurochem 2005, 93:1353-1360.
45. Visanji N.P., Mitchell S.N., O'Neill M.J., Duty S. Chronic pre-treatment with nicotine enhances nicotine-evoked striatal dopamine release and α6 and β3 nicotinic acetylcholine receptor subunit mRNA in the substantia nigra pars compacta of the rat. Neuropharmacology 2006, 50:36-46.
46. Lai A., Parameswaran N., Khwaja M., Whiteaker P., Lindstrom J.M., Fan H., et al. Long-term nicotine treatment decreases striatal α6* nicotinic acetylcholine receptor sites and function in mice. Mol Pharmacol 2005, 67:1639-1647.
47. 125I]Y0-α-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine. Neuroscience 2006, 137:565-572.
48. Lester H.A., Xiao C., Srinivasan R., Son C.D., Miwa J., Pantoja R., et al. Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery. AAPS J 2009, 11:167-177.
49. Giniatullin R., Nistri A., Yakel J.L. Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. Trends Neurosci 2005, 28:371-378.
50. Picciotto M.R., Addy N.A., Mineur Y.S., Brunzell D.H. It is not " either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 2008, 84:329-342.
51. Dani J.A., Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996, 16:905-908.
52. 125I]-epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. Neuropharmacology 2004, 46:1141-1157.